Earnings Call Summary | OraSure Technologies(OSUR.US) Q2 2024 Earnings Conference
Earnings Call Summary | OraSure Technologies(OSUR.US) Q2 2024 Earnings Conference
Operating loss was $2.7 million GAAP, non-GAAP operating income $3.3 million.The following is a summary of the OraSure Technologies Inc (OSUR) Q2 2024 Earnings Call Transcript:
以下是奧瑞許科技股份有限公司(OSUR)2024財年第二季度業績會議調用記錄摘要:
Financial Performance:
金融業績：
Q2 2024 total revenue was $54.3 million, core revenue at $35.4 million.
Operating loss was $2.7 million GAAP, non-GAAP operating income $3.3 million.
2024年第二季度總營業收入爲$54.3百萬，核心營業收入爲$35.4百萬。
按照GAAP標準計算，運營損失爲270萬美元，非GAAP標準下的運營收入達到330萬美元。
Business Progress:
業務進展：
Launched new FDA-cleared packaging for OraQuick HIV test, enhancing shipping efficiencies.
Expanded agreements with Exact Sciences and Variantyx for saliva collection devices.
推出了新的經過FDA認證的OraQuick HIV測試包裝，提高了物流效率。
與精密科學和Variantyx擴大了唾液採集設備協議。
Opportunity:
機會：
International diagnostics to lead sequential revenue increase from Q2 to Q3 2024.
Opportunities in liquid biopsy and animal health within Sample Management sector.
國際診斷將引領2024年第二季度到第三季度的業績增長。
在樣品管理板塊內，液體活檢和動物健康提供了機會。
Risk:
風險：
Continual adjustments required due to pandemic's impact on market.
Anticipated lower gross margins in Q3 from international diagnostics with lower margins.
由於疫情對市場的影響，需要持續調整。
預計國際診斷毛利率下降將導致2024年第三季度毛利率下降。
Financial Performance:
金融業績：
In Q2 2024, OraSure Technologies reported total revenue of $54.3 million, with core revenue (excluding COVID-19 products) at $35.4 million.
Diagnostic products revenue was $18.7 million, decreasing by 5% year-over-year.
Sample Management revenue reached $12.6 million, a decrease of 3% year-over-year.
Gross margin for Q2 stood at 45.4% on a GAAP basis and 47.4% non-GAAP.
Operating loss for the quarter was $2.7 million on a GAAP basis, while non-GAAP operating income was $3.3 million.
在2024年第二季度，奧瑞許科技報告總營業收入達到5430萬美元，核心營業收入(不包括COVID-19產品)達到3540萬美元。
診斷產品營業收入爲1870萬美元，同比下降了5%。
樣品管理營業收入爲1260萬美元，同比下降了3%。
按照GAAP標準計算，第二季度毛利率爲45.4%，非GAAP標準下的毛利率爲47.4%。
本季度按照GAAP標準計算，運營損失爲270萬美元，非GAAP標準下的運營收入達到330萬美元。
Business Progress:
業務進展：
OraSure launched new FDA-cleared packaging and labeling for its OraQuick HIV self test, expected to improve shipping efficiencies and reduce shelf space and plastic usage.
Achieved World Health Organization prequalification for OraQuick HCV self test.
Expanded agreement with Exact Sciences to supply saliva collection devices for hereditary cancer and therapy selection tests.
Broadened relationship with Variantyx for genetic testing using saliva collection kits.
Advanced operational efficiency initiatives, including consolidations and leveraging centers of excellence.
發佈了經過FDA認證的OraQuick HIV自測包裝和標籤，預期將提高物流效率、減少貨架空間和塑料用量。
OraQuick HCV自測獲得了世界衛生組織的預認證。
擴大了與精密科學合作，爲遺傳癌症和治療選擇測試提供唾液採集設備。
與Variantyx加強了基於唾液採集設備的基因檢測關係。
推進了運營效率改進措施，包括整合和利用卓越中心。
Opportunities:
機會：
Strengthened position in the diagnostics market with the expansion of the diagnostics portfolio, including the Syphilis Health Check.
International diagnostics expected to drive most of the sequential revenue increase from Q2 to Q3 2024.
Potential growth in global markets following the WHO prequalification for the OraQuick HCV self test.
Opportunities in the Sample Management sector, particularly with emerging growth segments like liquid biopsy and animal health.
擴展了診斷組合產品組合，包括梅毒健康檢查，鞏固了在診斷市場的地位。
預計國際診斷將推動2024年Q2至Q3中的大部分順序營業收入增長。
OraQuick HCV自我測試獲得WHO預認證後，全球市場潛力增長。
在樣本管理領域有機會，特別是液態活檢和動物健康等新興增長細分市場。
Risks:
風險：
Ongoing declines in certain business segments, like the 40% decrease in revenues from the Diversigen Molecular Sequencing Services that OraSure is exiting.
Lower gross margins anticipated in Q3 due to increased international diagnostics revenue, which carries lower margins. Winds down costs from exiting the Diversigen business also expected to impact margins short term.
Continual adjustment and recovery from the pandemic's impact on the market environment.
OraSure正在退出的Diversigen分子測序服務業務的營業收入減少了40%。
預計Q3的毛利率將下降，因爲國際診斷業務營業收入增長，該業務的毛利率較低。退出Diversigen業務的成本預計也會對短期利潤率產生影響。
持續調整和恢復受疫情影響的市場環境。
More details: OraSure Technologies IR
更多細節：奧瑞許科技IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。